Table 1.
Major radionuclides used for radioembolization of hepatocellular carcinoma.
| Radionuclides | Emission and energy (MeV) | Half-life | Maximum tissue penetration (mm) | Imaging type |
|---|---|---|---|---|
| 90Y | β 2.28 (100%) γ/ |
2.7 d | 12 | BS SPECT/ PET |
| 32P | β 1.71 (100%) γ/ |
14.3 d | 7.9 | BS SPECT/ PET |
| 131I | β 0.607 (99%) γ 0.364 (1%) |
8.04 d | 2 | SPECT |
| 188Re | β 2.12 (71.6%) 1.96 (25.1%) γ 0.155 (15%) |
16.9 h | 11 | SPECT |
| 166Ho | β 1.84 (50.5%) 1.74 (48.7%) γ 0.081 (6.2%) 0.00138(0.93%) |
1.1 d | 8.7 | SPECT/MR |
| 177Lu | β 0.176 (12.2%) 0.497 (78.6%) 0.384 (9.1%) γ 0.113 (6.4%) 0.208 (11%) |
6.7 d | 2.2 | SPECT |
| 153Sm | β 0.81 (20%) 0.71 (30%) 0.64 (50%) γ 0.103 (28%) |
46.3 h | 3 | SPECT |
| 186Re | β 2.13 (70%) 1.98 (26%) γ 0.155 (16.2%) 0.633 (1.6%) |
3.8 d | 4.5 | SPECT |